Phase 1-1b trial of mitochondrially targeted tamoxifen for metastatic solid tumors
Dr. Zuzana Bielcikova
Mitochondria present an emerging target for cancer treatment. MitoTam is a first-in-class mitochondrially targeted analog of tamoxifen. A phase 1-1b trial at Charles University (Prague, Czech Republic) evaluated MitoTam in patients with solid metastatic tumors, who terminated their standard oncological therapies. Toxicities included hematological adverse events, hyperthermia/fever, and thromboembolic complications. Clinical benefit was seen in 37% of patients, with the largest effect in patients with renal cell carcinoma (CBR 83%).
